Sharemaestro Newsreel

AimwellBio Publishes Investor Briefing on Acquired Trustr Intellectual Property Portfolio Valued at $10m Reinforcing Commitment to Transparency

Behavioral engagement technology carries documented institutional lineage spanning Oxford, the University of Vermont, Cornell, AMCP, and a Sanofi pilot program, as inventor Dr. Chris A. Jones joins AimwellBio's Board of Advisors and leads further expansion. MIAMI, FL / ACCESS Newswire / August 13, 2026 …

Big Tech Drives Up Credit Risk for Safe Firms With No AI Links

(Bloomberg) -- As a flood of debt sales by US tech companies ripples through the credit market, it seems to be triggering an inadvertent rise in risk metrics for some of the world's safest firms. Most Read from Bloomberg Walter Sells Lakers, Seeks More …

[Latest] Global Whey Protein Market Size/Share Worth USD 26.04 Billion by 2034 at a 7.56% CAGR: Custom Market Insights (Analysis, Outlook, Leaders, Report, Trends, Forecast, Segmentation, Growth, Growth Rate, Value)

Custom Market Insights [220+ Pages Latest Report] According to a market research study published by Custom Market Insights, the demand analysis of Global Whey Protein Market size & share revenue was valued at approximately USD 12.58 Billion in 2024 and is expected to reach …

Eurofins Scientific: Director/PDMR Shareholding

LUXEMBOURG, August 12, 2026--(BUSINESS WIRE)--Eurofins Scientific SE (EUFI.PA) has received various notifications of dealing from Persons Discharging Managerial Responsibilities ("PDMR"). The notification of Dealing Form for each PDMR can be found below. This notification is made in accordance with the European Market Abuse Regulation. …

National Vision Raises Outlook as Higher-Value Customers Fuel Breakout Quarter

By Karen Roman National Vision Holdings, Inc. (Nasdaq: EYE) said second quarter net revenue increased 2.5% to $498.8 million compared to the year prior and net income was $12.4 million against $8.7 million, with net income margin up to 2.5% from 1.8%. Diluted earnings …

Update: Market Chatter: Meta Platforms Faces German Criminal Complaint Over AI Smart Glasses

(Updates with response from a Meta Platforms spokesperson in the fourth paragraph.) Meta Platform PREMIUM Upgrade to read this MT Newswires article and get so much more. A Silver or Gold subscription plan is required to access premium news articles. Upgrade Already have a …

U.K. regulator reaffirms safety of childhood vaccination

[Syringe drawing liquid medication from medical vial] zhikun sun/iStock via Getty Images Days after President Donald Trump ordered major changes to the U.S. childhood immunization schedule, the U.K. drug regulator on Wednesday reaffirmed the safety of pediatric vaccination, noting it remains one of the …

Adagene Reports Six Months 2026 Financial Results and Provides Corporate Updates

Adagene Inc. Randomized Phase 2 trial in microsatellite stable colorectal cancer (MSS CRC) ongoing, with results expected in 1H 2027; potential registration trial expected in 2027 once recommended dose regimen has been established Data reported at AACR from triple combination therapy in 1L hepatocellular …

InduPro Closes $77 Million Series B Financing and Doses First Patient in Phase 1 Study of Lead Oncology Program IDP-001

IDP-001 is a bispecific antibody-drug conjugate targeting EGFR and a novel Tumor-Associated Proximity Antigen identified through InduPro's proximity-guided platform Phase 1 study is enrolling adults with advanced squamous non-small cell lung cancer and other solid tumors Financing led by The Column Group, with participation …

A Profitable Rare-Disease Prize: Who Might Snap Up BioCryst?

Quick Read BioCryst hit its first full year of profitability in 2025, with Q2 2026 revenue up 34% to $218 million, fueling acquisition speculation. Takeda (TAK) tops the buyer rankings as navenibart directly threatens its Takhzyro franchise; AstraZeneca (AZN) ranks second through its Alexion …

Why the Amlitelimab Setback Isn’t Enough to Sink Sanofi’s Multi-Billion Dollar Engine

It was reported on July 24 that Sanofi (NASDAQ:SNY) shares underperformed in European trading following the company's decision to drop the clinical development of its eczema candidate, amlitelimab, for moderate-to-severe atopic dermatitis. Rather than a fundamental breakdown, the move reflects an aggressive R&D pipeline …

Nurix Therapeutics' STAT6 Degrader Likely to Receive Increased Recognition, RBC Says

Nurix Therapeutics' (NRIX) STAT6 degrader NX-3911 is likely to receive increased recognition after advancing into clinical development under its collaboration with Sanofi (SNY), RBC Capital Markets said in a Monday research note.The investment firm said limited preclinical data Silver Upgrade to read this MT …

IPSEN - Buy-back programme - Art 5 of MAR - Week 32 - 2026

Ipsen Pharma Aggregated presentation by day and by market Weekly report on share repurchases from 04th August to 05th August 2026 Name of the Issuer Identify code of the Issuer Transaction day Identify code of the financial instrument Total daily volume (in number of …

Eurofins Scientific SE: Weekly Report on Share Repurchases from 03rd August to 07th August 2026

LUXEMBOURG, August 10, 2026--(BUSINESS WIRE)--Regulatory News: Eurofins Scientific SE (Paris:ERF): Name of the Issuer Identify code of the Issuer Transaction day Identify code of the financial instrument Total daily volume (in number of shares) Daily weighted average purchase price of the shares Market (MIC …

Eurofins Scientific SE: Disclosure of Total Number of Voting Rights and Number of Shares in the Capital at 31 July 2026

LUXEMBOURG, August 10, 2026--(BUSINESS WIRE)--Regulatory News: Eurofins (Paris:ERF): ANNEXE B Form to be used for the disclosure of the total number of voting rights and capital, in accordance with the law and grand-ducal regulation of 11 January 2008 on transparency requirements for issuers of …

Novavax (NVAX) Is Up 8.6% After Beating Q2 Estimates And Expanding Big-Pharma Partnerships - What's Changed

In early August 2026, Novavax reported Q2 2026 revenue of US$56.7 million, sharply lower than the prior year, and moved from net income to a net loss of US$53.39 million, translating into basic and diluted losses of US$0.32 per share from continuing operations. Alongside …

NVAX Q2 Earnings & Sales Beat Estimates, '26 Sales Outlook Raised

Novavax NVAX incurred a loss of 32 cents per share in the second quarter of 2026, narrower than the Zacks Consensus Estimate of a loss of 36 cents. In the year-ago quarter, the company had recorded earnings per share (EPS) of 62 cents, driven …

Résultats de EMEIS

« Notre chiffre d’affaires devrait progresser d’environ 10 % en 2026 », Belén Garijo, la nouvelle dirigeante de Sanofi revoit à la hausse les prévisions du groupe et poursuit la revue du pipeline

Inventiva annonce ses résultats financiers préliminaires pour le premier semestre 2026¹

MEDCL Prévisions - Objectif de prix pour 2027

ABVX Prévisions - Objectif de prix pour 2027

Aelis Farma : Mise à disposition du descriptif du programme de rachat d’actions

Medincell en forte baisse après les résultats annuels

Résultats de EssilorLuxottica

Legrand, EssilorLuxottica et Michelin sur le podium gagnant du Cac 40 après leurs résultats, le changement de direction chez Sanofi passe mal

Sanofi affiche sa confiance pour 2026 après des résultats 2025 supérieurs aux attentes

Sanofi annonce un chiffre d’affaires de plus de 43 milliards d’euros en 2025

Sanofi présente de bons résultats, mais déçoit les investisseurs

Sanofi va racheter pour un milliard d’euros d’actions après des résultats solides

Sanofi : légère hausse après les résultats

De nouvelles statistiques américaines au programme pour attendre les résultats d'Apple, Sanofi, Eurofins Scientific et STMicro sur le gril en France

Prévisions Action Sanofi 2026–2030 | Perspectives